SpaceX has been talking about point-to-point Earth transport on Starship since 2017. The concept is simple: use Starship as an ultra-fast suborbital vehicle to carry passengers anywhere on Earth in under an hour. New York to Tokyo in 37 minutes. London to Sydney in 51 minutes. The physics work. The question has always been whether the economics work.
With IFT-10 targeting June 2026 and Starship approaching operational status, that question is becoming urgent rather than theoretical.
The cost math starts with reusability. Each Starship flight costs approximately $10 million in propellant and operations when fully reusable — SpaceX's stated target. Divided across 100 passengers at a ticket price of $100,000 each, the revenue per flight is $10 million against a $10 million cost. That's breakeven at $100,000 per ticket before accounting for ground infrastructure, regulatory costs, and profit margin.
$100,000 per ticket is expensive. It's also cheaper than a private jet for long-haul routes and competitive with first-class commercial aviation for the longest city pairs. The initial market is not mass transit — it's the same market that currently pays $50,000-150,000 for private aviation on ultra-long-haul routes. That market is real and large.
The regulatory path is the harder problem. Point-to-point rocket transport requires overflying populated areas during ascent and descent, sonic boom management, FAA and international airspace coordination, and entirely new safety certification frameworks. None of these are solved. SpaceX is not currently pursuing FAA certification for passenger point-to-point service.
What is happening is that every successful Starship IFT makes the regulatory conversation more serious. IFT-10 catching the booster twice in a row changes the reliability narrative in a way that FAA regulators notice. The path from test vehicle to certified passenger transport is long — probably a decade — but IFT-10 is a step on that path.
The point-to-point business case shows up in the SpaceX IPO S-1 as a long-term revenue opportunity rather than a near-term line item. That's the right framing. It's not what you're buying when you buy SPCX in 2026. It's what you might own a piece of by 2035.